Retrospective State Medicaid Claims Analysis of Children and Adults With Obsessive-Compulsive Disorder

Psychiatr Serv. 2023 Nov 1;74(11):1185-1188. doi: 10.1176/appi.ps.20220152. Epub 2023 Apr 25.

Abstract

Objective: With a lifetime U.S. prevalence of 2.3%, obsessive-compulsive disorder (OCD) is a chronic condition often producing reduced quality of life and disability when left untreated. Little is known about the prevalence or treatment of diagnosed OCD in public behavioral health systems.

Methods: Using a claims analysis of 2019 New York State Medicaid data (N=2,245,084 children; N=4,274,100 adults), the authors investigated the prevalence and characteristics of children and adults with OCD. The authors also examined whether these individuals received treatment with medication or psychotherapy.

Results: The prevalence of OCD was 0.2% among children and 0.3% among adults. Fewer than half of children (40.0%) and adults (37.5%) received U.S. Food and Drug Administration-approved medications (with or without psychotherapy); another 19.4% of children and 11.0% of adults received 45- or 60-minute psychotherapy alone.

Conclusions: These data demonstrate the need for public behavioral health systems to increase their capacity to identify and treat OCD.

Keywords: Medicaid; Obsessive-compulsive disorder; Prevalence; Serotonin reuptake inhibitor; Treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Child
  • Humans
  • Insurance Claim Review
  • Medicaid
  • Obsessive-Compulsive Disorder* / epidemiology
  • Obsessive-Compulsive Disorder* / therapy
  • Quality of Life
  • Retrospective Studies
  • Selective Serotonin Reuptake Inhibitors*

Substances

  • Selective Serotonin Reuptake Inhibitors